News

Video

Hormone Replacement Therapy Linked to Greater IBS, Gastric Motility Disorder Risk

Key Takeaways

  • Hormone replacement therapy is linked to increased risk of IBS and gastric motility disorders in postmenopausal women.
  • Studies showed elevated gastrointestinal symptoms and medication use in women on hormone therapy.
SHOW MORE

Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.

Hormone replacement therapy is associated with an increased risk of developing irritable bowel syndrome (IBS) and gastric motility disorders in postmenopausal women, according to findings from a pair of studies presented at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania.

Building upon prior hypotheses that female sex hormones influence the higher prevalence of IBS and gastric motility disorders in women, the studies explored the role hormone replacement therapy plays in this risk and found it was linked to an increased likelihood of developing IBS and gastric motility disorders as well as elevated gastrointestinal symptoms, medication utilization, and diagnostic testing.

“What ultimately inspired me is the lack of current data that's out there. In the GI clinic that I work in, we see an increased population of women that come in with functional GI disorders, and I think there is a huge need for continued research really paying attention to what other things potentially could be contributing to this, their underlying gastrointestinal diagnosis,” Jacqueline Khalil, DO, an internal medicine resident at Case Western Reserve University/MetroHealth, explained to HCPLive.

In her studies, Khalil examined data for postmenopausal women ≥ 50 years of age with and without hormone replacement therapy, including estrogen and progesterone, to compare their risk of developing IBS and gastric motility disorders.

Findings showed postmenopausal women prescribed hormone replacement therapy had a greater risk of developing IBS (Odds ratio [OR], 1.75; 95% CI, 1.58-1.94) and gastric motility disorders including gastroparesis or functional dyspepsia (OR, 1.39; 95% CI, 1.16-1.68). Additionally, in both studies, a hormone therapy prescription was associated with elevated GI symptoms and medication prescription.

Khalil noted neither study looked at the independent effects of estrogen versus progesterone, citing this as a potential avenue for future research. Additionally, she called attention to the role this research could play in informing IBS and gastric motility disorder treatment in the future.

Editors' note: Khalil has no relevant disclosures.

References

  1. Khalil J, Sun Y, Kaelber D, et al. P2357 - Hormone Replacement Therapy Is Associated With Increased Risk of Developing Irritable Bowel Syndrome in Post-Menopausal Women. Paper presented at: ACG 2024 Annual Scientific Meeting. Philadelphia, Pennsylvania. October 25-30, 2024.
  2. Khalil J, Sun Y, Kaelber D, et al. P3327 - The Association Between Hormone Replacement Therapy and Gastric Motility Disorders in Post-Menopausal Women. Paper presented at: ACG 2024 Annual Scientific Meeting. Philadelphia, Pennsylvania. October 25-30, 2024.
Related Videos
Ahmad Masri, MD, MS: Reaching New Milestones in Cardiovascular Gene Therapy Development
Naim Alkhouri, MD | Credit: Naim Alkhouri on X
Age, Race, Ethnicity Disparities Hinder Celiac Disease Screening, with Debra Silberg, MD, PhD
Lauren Collen, MD: Advanced Combination Therapy May Be Effective Option for Pediatric Refractory IBD
Lauren Collen, MD: Some Fragrances May be More Prevalent in Exposomes of Children with Crohn’s Disease
Impact of Long Hospital Stays on Pediatric Gastroparesis Management with Christian Sadaka, MD
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Braden Kuo, MD | Credit: Mass Gen
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
© 2024 MJH Life Sciences

All rights reserved.